Description

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8 and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca2+ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a bombesin antagonist, and inhibits the growth of small cell lung cancer[1][2][3]—–C79H109N19O12—-[1]Woll PJ, Rozengurt E. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1859-63.|[2]Jarpe MB, et al. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem. 1998 Jan 30;273(5):3097-104.–96736-12-8–1516.83—-CC(C)C[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@@H](CC1=CNC2=CC=CC=C12)NC([C@H](CC3=CC=CC=C3)NC([C@H](NC([C@H](CCC(N)=O)NC([C@@H](CC4=CC=CC=C4)NC([C@H]5N(CCC5)C([C@H](CCCCN)NC([C@H]6N(CCC6)C([C@H](N)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)CC7=CNC8=CC=CC=C78)=O)=O)=O)=O–Cancer; Inflammation/Immunology–10 mM in DMSO–Bombesin Receptor;Interleukin Related;JNK—-GPCR/G Protein;Immunology/Inflammation;MAPK/ERK Pathway–Peptides